Repeated administration of an intravenous immunoglobulin containing antibody to hepatitis B e antigen (anti-HBe) and antibody to hepatitis B core antigen (anti-HBc) but free of antibody to hepatitis B surface antigen (anti-HBs) before and after the inoculation of 104-9 50% chimpanzee infective doses of hepatitis B virus (HBV) markedly prolonged the incubation period of HBV in experimentally infected chimpanzees. Similar administration of an immunoglobulin preparation containing anti-HBc but free of anti-HBe and anti-HBs or intramuscular administration of a single dose of immunoglobulin containing anti-HBe and anti-HBc 3 days before or after inoculation with HBV did not appear to modulate HBV infection. These observations suggested that anti-HBe, or an unidentified antibody associated with it, may have biological activity in the modulation of HBV replication.
The generally low titers of hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg) carriers positive for antibody to hepatitis B e antigen (anti-HBe) originally suggested the hypothesis that anti-HBe might modulate HBV replication (12) . To test this hypothesis, two seronegative chimpanzees were immunized with three injections of hepatitis B e antigen (HBeAg) containing plasma free of detectable HBsAg. Thirty-two weeks after the first immunization, both animals were challenged with 103-5 50% chimpanzee infective doses (CID50) of the NIH HBV/ayw challenge material. Neither of the HBeAg-immunized animals developed HBsAg (13) .
Because it was difficult to rule out the possibility that results were affected by undetectable amounts of HBsAg in the antigen preparation used for immunization, we decided to evaluate this hypothesis further by testing the effect of passive immunization with anti-HBe immunoglobulin (HBeIG) free of antibody to hepatitis B surface antigen (antiHBs) on experimental HBV infection in the chimpanzee model.
The results of these studies provide further support for the postulated biological activity of anti-HBe, although the possibility that the observed effects indicate activity of an unmeasured antibody present with anti-HBe cannot be excluded.
(A preliminary report of the present study was 4 h at room temperature for a total of three adsorptions. The final Ausria positive control/negative control (P/N) ratio was 4.0 (borderline positive). The plasma was treated with 0.31 ml of P-propiolactone per 100 ml.
Immunoglobulin was isolated by Cohn ethanol fractionation (6) and made up to a 4 g% solution, which was sterile filtered. The final produt. contained 99% immunoglobulin G, had an anti-HBe titer of 1:32 to 1:64 as determined by gel diffusion, and was negative for HBsAg and anti-HBs in Ausria II and Ausab radioimmunoassays (Abbott Laboratories, North Chicago, Ill.). The recovery of anti-HBe was in accordance with expectations for immune serum globulin production (11) .
Preparation of IV-HBeIG. Anti-HBe plus anti-HBc intravenous (i.v.) immunoglobulin (IV-HBeIG) was prepared by a modification of the method of Stephan (15) . Five liters of plasma from chronic HBsAg carriers with an average antiHBe titer of 1:8 as determined by gel diffusion were successively adsorbed with 2 g of Aerosil 380 per 100 ml for 4 (14) for isolation of immune complexes. The final polyethylene glycol precipitates were suspended in 3 M NaSCN and adsorbed to polystyrene balls which were subsequently probed for HBsAg with 125I-labeled anti-HBs as described by Neurath et al. (8) .
Chimpanzees. Ten chimpanzees caught in the wild and ranging in age from 2 to 6 years were used in these studies. These animals were quarantined for a minimum of 6 tnonths before the start of experiments, were free of any markers of HBV infection, and had transaminases in the normal range. The animals had not been used in any previous experiment. Animals were housed in pairs in large, outdoor, screened, roofed cages at least 20 ft (6.1 m) apart. Precautions were taken to avoid the transmission of infection among groups of animals.
Laboratory tests. Blood samples were obtained from chimpanzees biweekly during quarantine and weekly during experimental protocols. Venous blood was allowed to clot, and then it was promptly separated and tested on the same day in Liberia for alanine aminotransferase (ALT) and aspartate aminotransferase by kinetic spectrophotometric assay and for HBsAg by Ausria II (Abbott Laboratories). The geometric mean alanine aminotransferase in normal chimpanzees was found to be 14.8 IU/liter with a range (+2 standard deviations) of 8.9 to 24.5 IU/liter. Additional tests for HBsAg, anti-HBs, anti-HBc, and anti-HBe were carried out at The New York Blood Center with radioimmunoassay reagent kits provided by Abbott Laboratories. RESULTS Application of IM-HBeIG. Two chimpanzees received 3.0 ml of the IM-HBeIG 3 days before i.v. inoculation of 103.0 CID50 of NIH HBV/adw, and two were given IM-HBeIG 3 days after the i.v. inoculation. This dose of this inoculum was reported to have produced hepatitis infections with incubation periods before the appearance of HBsAg which varied from 9 to 19 weeks in four chimpanzees (16 Effect of IV-HBeIG on HBV infection. Two seronegative chimpanzees (no. 156 and 166, weighing 23 and 25 kg, respectively) were given 0.5 ml of IV-HBeIG per kg five or six times at 6-week intervals. One day after the first immunoglobulin administration, both animals were inoculated i.v. with 10 ml of a 10-5 dilution of The New York Blood Center HBV/adw challenge virus, estimated to contain between 103 and 104.9 CID50. This dose is estimated to produce infection with an incubation period of 6.3 weeks with a 95% confidence interval of ±5.5 weeks (9). This virus stock has infected chimpanzees with 1 ml of 10-7 dilution (unpublished data).
Chimp 156 developed HBsAg 24 weeks after inoculation, a significant delay in onset (Fig. 1) . Chimp 166 did not develop HBsAg until 49 weeks after inoculation, an extraordinary prolongation of the expected incubation period. HBsAg did not appear in this animal until anti-HBe levels had fallen to nondetectable levels. HBsAg persisted for 3 weeks and was followed by development of strong anti-HBc and anti-HBs responses.
Effect of anti-HBc i.v. immunoglobulin on HBV infection. To further evaluate the relative roles of anti-HBe and antiHBc in causing the modulation of HBV infection observed in the previous experiment, we carried out an identical experiment with an i.v. immunoglobulin preparation containing anti-HBc but not anti-HBe. Two chimpanzees (no. 183 and 207) were given 0.5 ml of the i.v. immunoglobulin containing only anti-HBc per kg as described above. This dosage was repeated at 6-week intervals until HBsAg developed. One day after the first immunoglobulin injection, the animals were inoculated i.v. with 10 ml of a 10' dilution of The New York Blood Center HBV/adw challenge virus, estimated to contain 104.9 CID5o-Chimp 207 developed HBsAg in week 7 after inoculation, well within the expected incubation period (Fig. 2) . Chimp 183 developed what we consider to be a nonspecific crossreacting Ausab positivity which appeared on the day of inoculation and persisted for 8 weeks. HBsAg then appeared in week 12. The probable cross-reacting anti-HBs which appeared may have contributed to the delay in appearance of HBsAg in this animal. Neither animal had detectable antiHBe before infection.
VOL. 51, 1984 Search for sequestered HBsAg in immunoglobulin preparations. It could be postulated that the modulation of HBV infection in chimpanzees receiving HBeIG could reflect an immunizing effect of HBsAg sequestered in immune complexes and thus undetectable by radioimmunoassay. We therefore tested the two i.v. immunoglobulins for sequestered 1-BsAg by a method which has been shown to be capable of detecting 15 ng of HBsAg per ml in the presence of a 20,000-fold excess of anti-HBs (8) . No HBsAg was detectable. In control experiments, HBsAg was readily detectable in the presence of 10,000-fold excess anti-HBs (data not shown). DISCUSSION The marked prolongation of the incubation period before the appearance of HBsAg which was observed in chimpanzees repeatedly injected with HBeIG and which was not observed in animals which received repeated injections of an anti-HBc-containing immunoglobulin preparation is compatible with the postulated modulating activity of anti-HBe.
The IV-HBeIG was derived from HBsAg-containing plasma from which all detectable HBsAg had been removed by successive adsorptions with insoluble silicic acid (Aerosil 380). It could be argued that immune complexed HBsAg may not have been removed by this procedure and that this failure could account for the observed prolongation of the incubation periods. To investigate this possibility, we ap- As no antiHBs was detectable in these immunoglobulin preparations, such a great excess of anti-HBs cannot have been present; thus, the method should have been even more sensitive. These tests revealed no evidence of the presence of sequestered HBsAg in these preparations. Furthermore, no antiHBs response was observed in these animals as a result of the immunoglobulin administration. The Ausab test positivity found in chimp 188 appeared before the immunoglobulin injection. This positivity, as well as the weak Ausab reactants seen in two sera from chimp 156 and one serum from chimp 166, are probably non-HBV-related cross-reacting antibodies, which we have frequently observed appearing transiently in uninoculated animals (9, 12, 13 ). An alternative explanation for the observed prolongation of incubation periods is the possible presence of non-A-non-B virus(es) in the immunoglobulin preparation. This possibility is unlikely since this preparation was treated with Ppropiolactone and Aerosil adsorbtion, procedures which are known to inactivate non-A-non-B viruses (9, 10; Prince, unpublished data). Furthermore, monthly examinations by electron microscope of liver biopsies failed to reveal the characteristic non-A-non-B-related cytoplasmic ultrastructural changes in biopsies taken from chimps 156 and 166. The delta agent also cannot be implicated since it requires HBV replication.
HBeAg is a specificity present on the hepatitis B core antigen (HBcAg) polypeptide (7, 17) . This polypeptide appears to be present on the membrane of HBV-infected liver cells since HBcAg has been demonstrated by immunofluorescence on such cells after elution of bound anti-HBc (18) and since sera containing anti-HBc and anti-HBe have been found to block the effect of cytotoxic T cells on autologous infected liver cells in vitro (3). It is thus possible that antiHBe combines with this polypeptide on the surfaces of infected liver cells, resulting in a modulation of virus replication in a manner similar to that observed in measles virusinfected cells exposed to extracellular antibody to measles virus proteins (4) .
The mechanism of antibody-mediated modulation in viral infection remains speculative. It is known that antibody to viral antigen exposed on the cell membrane can induce capping, cocapping with histocompatibility antigens, and disappearances of the capped antigens from the cell surface as a result of endocytosis (reviewed in reference 2). Such changes in the membranes of infected cells could alter viral replication in unknown ways or possibly could hinder virus release from infected cells, thus inhibiting cell-to-cell spread. The latter could result in sufficient slowing of the recruitment of infected cells to permit various host immune mechanisms to come into play, resulting in effective termination of infection before the onset of clinical disease.
The failure to observe prolonged incubation periods in chimpanzees given a single dose of an IM-HBeIG preparation could be due to inadequate antibody levels, persisting for inadequate periods of time. After i.m. administration, specific antibody does not reach peak levels in the circulation before day 5 (1) . This is 2 days after virus inoculation in the pre-exposure experiment and 8 days after inoculation in the postexposure study. In the study with IV-HBeIG, passive antibody was present at high levels from the time of virus inoculation until more than 36 weeks after inoculation. Nevertheless, moderate prolongation of the incubation period should have been observed after the i.m. administration. However, due to the inherent variability of incubation periods (95% confidence interval + 5.5 weeks when two animals are used [9] ), detection of a moderate prolongation is difficult.
Although we favor the interpretation that anti-HBe is the biologically active antibody in the IV-HBeIG used in this study, we cannot exclude the possibility that 
